Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

Trial ID or NCT#

NCT01707264

Status

NOT RECRUITING

Purpose

Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30
subjects with AL amyloidosis. Expansion phase to evaluate safety, efficacy and
pharmacokinetics of NEOD001 in 25 additional subjects at the maximum tolerated dose.

Official Title

A Phase 1/2, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No

Inclusion Criteria:

Males and females aged ≥18 years;

ECOG performance status (PS) 0-2;

Diagnosis of systemic AL amyloidosis (subjects with non-AL amyloidosis are not eligible);

Received at least one prior systemic therapy, which may include stem cell transplant, for AL amyloidosis;

Have adequate organ function;

Ability to understand and willingness to sign informed consent prior to initiation of any study procedures.

Exclusion Criteria:

Secondary or familial amyloidosis;

Life expectancy of < 3 months;

Symptomatic multiple myeloma;

Hypersensitivities to other monoclonal antibodies;

Known HIV infection;

Women who are lactating;

Any other condition or prior therapy, which in the opinion of the PI, would make the subject unsuitable for the study.